Garima Baral

This study shows that suppressing PP2A-B56α promotes EMT in EGFR mutant NSCLC by reducing epithelial markers and increasing mesenchymal markers, leading to migratory and invasive phenotypes.

This study shows that activating PP2A-B56 in PDAC increases EGFR signaling and promotes tumor growth, suggesting a new therapeutic target.

This study shows that PP2A activation inhibits macropinocytosis and induces cell death in pancreatic ductal adenocarcinoma, suggesting PP2A activators could be used with metabolic inhibitors as a new therapeutic strategy.